Skip to content

Study · Randomized controlled trial · n = 33 · 1986

3 results

Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone.

Rajfer J, Handelsman DJ, Swerdloff RS, Hurwitz R, Kaplan H, Vandergast T, Ehrlich RM

The New England journal of medicine1 Feb 1986Cited by 73 (Europe PMC)

PMID2868413 (opens in a new tab)DOI10.1056/nejm198602203140802 (opens in a new tab)PepBankPUB-02868413
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In boys with cryptorchidism, testicular descent occurred in 1 of 17 receiving hCG versus 3 of 16 receiving GnRH, without significant difference.

    In plain wordsIn boys with cryptorchidism, testicular descent did not differ significantly between hCG and GnRH treatment.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    No significant changeTesticular descent in cryptorchidism
    Study

    n = 33

    Comparator
    Intranasal gonadotropin-releasing hormone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3300 IU per week · parenteral · four weeksAs given in this study (human).

    Measurements

    Testicular descent
    6%
    hCG group, 1 of 17
    Testicular descent
    1 patients
    hCG group, of 17
    Testicular descent
    19%
    GnRH group, 3 of 16
    Testicular descent
    3 patients
    GnRH group, of 16
    P value
    0.23 p value
    Testicular descent in cryptorchidism, GnRH versus hCG

    Source sentences

    Summary
    Testicular descent into the scrotum occurred in 3 of the 16 patients (19 percent) treated with gonadotropin-releasing hormone and in 1 of the 17 (6 percent) treated with human chorionic gonadotropin (P = 0.23).
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind study comparing intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days) with parenteral human chorionic gonadotropin (3300 IU per week for four weeks) in the treatment of cryptorchidism
    Summary · context
    in 33 boys one to five years old (29 with unilateral and 4 with bilateral cryptorchidism).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In boys with cryptorchidism, testosterone increased in both groups, but levels were significantly higher with hCG than with GnRH.

    In plain wordsIn boys with cryptorchidism, testosterone increased with both treatments but reached higher levels with hCG than with GnRH.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    IncreaseTestosterone during treatment
    Study

    n = 33

    Comparator
    Gonadotropin-releasing hormone
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3300 IU per week · parenteral · four weeksAs given in this study (human).

    Measurements

    P value
    < 0.05 p value
    Testosterone levels during treatment, hCG versus GnRH

    Source sentences

    Summary
    During treatment, the testosterone levels were significantly increased in both groups, but higher levels occurred in the group treated with human chorionic gonadotropin (P less than 0.05).
    2 context sentences
    Summary · context
    We conducted a randomized, double-blind study comparing intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days) with parenteral human chorionic gonadotropin (3300 IU per week for four weeks) in the treatment of cryptorchidism
    Summary · context
    in 33 boys one to five years old (29 with unilateral and 4 with bilateral cryptorchidism).
  3. 03HumanNon-randomized trialEfficacy outcome

    In five boys with retractile testes, all had testicular descent during hCG treatment in an uncontrolled study.

    In plain wordsIn five boys with retractile testes, all had testicular descent during hCG treatment in an uncontrolled study.

    Peptide
    hCG (human chorionic gonadotropin)
    Outcome
    IncreaseTesticular descent in retractile testes
    Study

    n = 5

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    3300 IU per week · parenteral · four weeksAs given in this study (human).

    Source sentences

    Summary
    who were originally excluded from the main protocol but were treated with the same regimen of human chorionic gonadotropin, descent into the scrotum occurred in all patients.
    1 context sentence
    Summary · context
    In a parallel (but uncontrolled) study of five boys with retractile testes

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.